Protocol Ledger

NCT06708299 · Phase III · RECRUITING

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Interventional Phase III clinical trial protocol NCT06708299 sponsored by Cardiol Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-07 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06708299
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06708299
Protocol FieldVerified Registry Value
NCT IdentifierNCT06708299
Consolidated Lead SponsorCardiol Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2025-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI